Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis

American Journal of Kidney Diseases

Volumn 49, Issue 6, 2007, Pages 814-823

  Greenbaum, Larry A ^a   Benador, Nadine ^b   Goldstein, Stuart L ^c   Paredes, Ana ^d   Melnick, Joel Z ^e   Mattingly, Susan ^e   Amdahl, Michael ^e   Williams, Laura A ^e   Salusky, Isidro B ^f  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d MIAMI CHILDREN'S HOSPITAL   (United States)

^e ABBOTT LABORATORIES   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

children; end stage renal disease; hemodialysis; Paricalcitol; secondary hyperparathyroidism

Indexed keywords

PARATHYROID HORMONE; PARICALCITOL; PLACEBO; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MALE; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS;

EID: 34249081159     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.03.008     Document Type: Article

References (32)

1. Pitts T.O., Piraino B.H., Mitro R., et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67 (1988) 876-881
2. Slatopolsky E., and Delmez J.A. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23 (1994) 229-236
3. Lopez H., Dusso A.S., Rapp N.S., Martin K.J., and Slatopolsky E. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 259 (1990) F432-F437
4. Goodman W.G. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59 (2001) 1187-1201
5. 3 in childhood renal osteodystrophy. N Engl J Med 298 (1978) 238-242
6. 3 or 1,25-dihydroxycholecalciferol. Proc Eur Dial Transplant Assoc Eur Ren Assoc 16 (1979) 644-648
7. 3 in pre-dialysis renal bone disease. Clin Endocrinol (Oxf) 7 suppl (1977) S109-S116
8. 3. Clin Endocrinol (Oxf) 7 suppl (1977) S117-S124
9. Ramirez J.A., Goodman W.G., Belin T.R., Gales B., Segre G.V., and Salusky I.B. Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. Am J Physiol 267 (1994) E961-E967
10. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., and Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74 (1984) 2136-2143
11. Sprague S.M., and Moe S.M. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 19 (1992) 532-539
12. Greenbaum L.A., Grenda R., Qiu P., et al. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 20 (2005) 622-630
13. Ho M., and Stablein D.M. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Annual Report (2002), NAPRTCS, Rockville, MD
14. Delmez J.A., Tindira C., Grooms P., Dusso A., Windus D.W., and Slatopolsky E. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 83 (1989) 1349-1355
15. Silver J., Naveh-Many T., Mayer H., Schmelzer H.J., and Popovtzer M.M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78 (1986) 1296-1301
16. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42 suppl 3 (2003) S1-S201
17. Salusky I.B., Kuizon B.D., Belin T.R., et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int 54 (1998) 907-914
18. Slatopolsky E., Finch J., Denda M., et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97 (1996) 2534-2540
19. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
20. Milliner D.S., Zinsmeister A.R., Lieberman E., and Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38 (1990) 931-936
21. Oh J., Wunsch R., Turzer M., et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106 (2002) 100-105
22. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., and Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 (2004) 2208-2218
23. Sprague S.M., Llach F., Amdahl M., Taccetta C., and Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63 (2003) 1483-1490
24. Martin K.J., Gonzalez E.A., Gellens M., Hamm L.L., Abboud H., and Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9 (1998) 1427-1432
25. Nussbaum S.R., Zahradnik R.J., Lavigne J.R., et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33 (1987) 1364-1367
26. Salusky I.B., Ramirez J.A., Oppenheim W., Gales B., Segre G.V., and Goodman W.G. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45 (1994) 253-258
27. Salusky I.B., Goodman W.G., Kuizon B.D., et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63 (2003) 1801-1808
28. Salusky I.B. Bone and mineral metabolism in childhood end-stage renal disease. Pediatr Clin North Am 42 (1995) 1531-1550
29. Yang H., Curinga G., and Giachelli C.M. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 66 (2004) 2293-2299
30. Chavers B.M., Li S., Collins A.J., and Herzog C.A. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 62 (2002) 648-653
31. Lindberg J., Martin K.J., Gonzalez E.A., Acchiardo S.R., Valdin J.R., and Soltanek C. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56 (2001) 315-323
32. Salusky I.B., Goodman W.G., Sahney S., et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 16 (2005) 2501-2508